Ireland
--:--IST
Enrolling by invitation Observational

Enhancing Scleral Lens Fit With Advanced Imaging

NCT06751615 · tracked via the Priya Life Science Spain tracker
Sponsor
Fernando Fernandez Velazquez
Phase
Observational
Started
2024-12-01
Last updated
2024-12-30

Condition(s) studied

KeratoconusAstigmatism High

Study summary

The goal of this experimental clinical trial is to enhance the predictability and precision of scleral lens fitting in patients with complex corneal conditions such as keratoconus, post-surgical irregularities, and severe dry eye syndrome. The main questions it aims to answer are:

Can detailed sagittal height measurements obtained from the Oculus Pentacam Corneal Scleral Profile (CSP) predict the necessary adjustments for optimal scleral lens fit? Will the use of these measurements reduce the number of trial-and-error adjustments needed to achieve an ideal fit, thereby reducing chair time and improving patient satisfaction?

Participants will:

Undergo detailed corneal and scleral tomography using the Oculus Pentacam with the CSP strategy.

Receive customized ICD 16.5 mm scleral lenses based on precise measurements of their ocular surface.

Participate in follow-up assessments to evaluate the fit of the lenses and provide feedback on comfort and visual outcomes.

This study focuses on a specific participant population of adults aged 18 and older who have not had success with other types of contact lenses. By leveraging advanced imaging technologies, the research aims to streamline the fitting process for scleral lenses, potentially setting new standards for treatment efficacy in specialty contact lens practices.

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Age 18 years and older. Diagnosed with keratoconus, post-corneal transplant irregularities, or severe dry eye disease, which are indicated for scleral lens usage. Previous intolerance or inability to use other types of contact lenses such as soft or rigid gas-permeable lenses. Willing and able to comply with scheduled visits, treatment plan, and other study procedures. Adequate ocular health suitable for contact lens wear, except for conditions being treated in the study. Ability to give informed consent. Exclusion Criteria: * Under 18 years of age. Active ocular infection or inflammation. History of herpetic keratitis. Severe allergies or contraindications to any component of the scleral lenses or imaging dyes used in the study. Any condition which, in the opinion of the investigator, may interfere with safe participation in the study or adherence to study procedures. Participation in another simultaneous clinical trial that might confound the results of the current study. Pregnant or breastfeeding women.

Primary outcome measure(s)

  • Predictive Accuracy of Sagittal Height for Scleral Lens Fit — Throughout the study duration, from initial measurement to final lens fitting (approximately 6 months)
    This primary outcome measure evaluates the predictive accuracy of sagittal height measurements obtained using the Oculus Pentacam at 10 mm, limbus, and 15 mm in determining the necessary adjustments to achieve optimal scleral lens fit. The main goal is to establish how closely the sagittal heights at these specific points predict the required lens sagittal depth to achieve a targeted central vault of approximately 300 microns. This outcome will assess the effectiveness of using Pentacam CSP data to reduce the number of fitting sessions and adjustments, thereby increasing the efficiency of the scleral lens fitting process. The expected result is a validated predictive model correlating specific sagittal height measurements with precise lens fitting parameters, potentially setting new standards for custom scleral lens adaptations.

Trial sites (1)

FacilityCityRegionStatus
Centro de Miopia Fernandez-Velazquez Madrid Spain
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06751615 on ClinicalTrials.gov ↗ ← All trials in Spain